Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-100.64%
operating margin TTM
-78.56%
revenue TTM
10.44 Million
revenue per share TTM
0.05$
valuation ratios | |
|---|---|
| pe ratio | -18.80 |
| peg ratio | -1.46 |
| price to book ratio | -5.24 |
| price to sales ratio | 19.05 |
| enterprise value multiple | -18.85 |
| price fair value | -5.24 |
profitability ratios | |
|---|---|
| gross profit margin | 93.14% |
| operating profit margin | -78.56% |
| pretax profit margin | -102.07% |
| net profit margin | -100.64% |
| return on assets | -57.2% |
| return on equity | 31.67% |
| return on capital employed | -166.38% |
liquidity ratios | |
|---|---|
| current ratio | 1.23 |
| quick ratio | 1.17 |
| cash ratio | 0.76 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 406.46 |
| operating cycle | 540.72 |
| days of payables outstanding | 209.24 |
| cash conversion cycle | 331.48 |
| receivables turnover | 2.72 |
| payables turnover | 1.74 |
| inventory turnover | 0.90 |
debt and solvency ratios | |
|---|---|
| debt ratio | 2.05 |
| debt equity ratio | -0.99 |
| long term debt to capitalization | -3.28 |
| total debt to capitalization | -116.32 |
| interest coverage | -6.05 |
| cash flow to debt ratio | -0.24 |
cash flow ratios | |
|---|---|
| free cash flow per share | -3.02 |
| cash per share | 3.68 |
| operating cash flow per share | -3.00 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -0.24 |
| short term coverage ratios | -1.07 |
| capital expenditure coverage ratio | -106.37 |
Frequently Asked Questions
When was the last time BridgeBio Pharma, Inc. (NASDAQ:BBIO) reported earnings?
BridgeBio Pharma, Inc. (BBIO) published its most recent earnings results on 10-08-2026.
What is BridgeBio Pharma, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. BridgeBio Pharma, Inc. (NASDAQ:BBIO)'s trailing twelve months ROE is 31.67%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. BridgeBio Pharma, Inc. (BBIO) currently has a ROA of -57.2%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did BBIO's net profit margin stand at?
BBIO reported a profit margin of -100.64% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is BBIO's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.23 in the most recent quarter. The quick ratio stood at 1.17, with a Debt/Eq ratio of -0.99.